Literature DB >> 32398326

Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617.

Maria Thor1, Joseph O Deasy2, Chen Hu3, Elizabeth Gore4, Voichita Bar-Ad5, Clifford Robinson6, Matthew Wheatley7, Jung Hun Oh1, Jeffrey Bogart8, Yolanda I Garces9, Vivek S Kavadi10, Samir Narayan11, Puneeth Iyengar12, Jacob S Witt13, James W Welsh14, Cristopher D Koprowski15, James M Larner16, Ying Xiao17, Jeffrey Bradley18.   

Abstract

PURPOSE: To quantitatively predict the impact of cardiopulmonary dose on overall survival (OS) after radiotherapy for locally advanced non-small cell lung cancer. EXPERIMENTAL
DESIGN: We used the NRG Oncology/RTOG 0617 dataset. The model building procedure was preregistered on a public website. Patients were split between a training and a set-aside validation subset (N = 306/131). The 191 candidate variables covered disease, patient, treatment, and dose-volume characteristics from multiple cardiopulmonary substructures (atria, lung, pericardium, and ventricles), including the minimum dose to the hottest x% volume (Dx%[Gy]), mean dose of the hottest x% (MOHx%[Gy]), and minimum, mean (Mean[Gy]), and maximum dose. The model building was based on Cox regression and given 191 candidate variables; a Bonferroni-corrected P value threshold of 0.0003 was used to identify predictors. To reduce overreliance on the most highly correlated variables, stepwise multivariable analysis (MVA) was repeated on 1000 bootstrapped replicates. Multivariate sets selected in ≥10% of replicates were fit to the training subset and then averaged to generate a final model. In the validation subset, discrimination was assessed using Harrell c-index, and calibration was tested using risk group stratification.
RESULTS: Four MVA models were identified on bootstrap. The averaged model included atria D45%[Gy], lung Mean[Gy], pericardium MOH55%[Gy], and ventricles MOH5%[Gy]. This model had excellent performance predicting OS in the validation subset (c = 0.89).
CONCLUSIONS: The risk of death due to cardiopulmonary irradiation was accurately modeled, as demonstrated by predictions on the validation subset, and provides guidance on the delivery of safe thoracic radiotherapy. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32398326      PMCID: PMC7877447          DOI: 10.1158/1078-0432.CCR-19-2627

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture.

Authors:  Joseph O Deasy; Søren M Bentzen; Andrew Jackson; Randall K Ten Haken; Ellen D Yorke; Louis S Constine; Ashish Sharma; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships.

Authors:  I El Naqa; G Suneja; P E Lindsay; A J Hope; J R Alaly; M Vicic; J D Bradley; A Apte; J O Deasy
Journal:  Phys Med Biol       Date:  2006-10-19       Impact factor: 3.609

3.  Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer.

Authors:  Jessika A Contreras; Alexander J Lin; Ashley Weiner; Christina Speirs; Pamela Samson; Daniel Mullen; Jian Campian; Jeffrey Bradley; Michael Roach; Clifford Robinson
Journal:  Radiother Oncol       Date:  2018-05-30       Impact factor: 6.280

4.  Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Christina K Speirs; Todd A DeWees; Sana Rehman; Alerson Molotievschi; Maria A Velez; Daniel Mullen; Sandra Fergus; Marco Trovo; Jeffrey D Bradley; Cliff G Robinson
Journal:  J Thorac Oncol       Date:  2016-10-12       Impact factor: 15.609

5.  Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy.

Authors:  Barbara Stam; Erik van der Bijl; Judi van Diessen; Maddalena M G Rossi; Angela Tijhuis; José S A Belderbos; Eugène Damen; Jan-Jakob Sonke
Journal:  Radiother Oncol       Date:  2017-09-19       Impact factor: 6.280

6.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Authors:  Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

7.  Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation.

Authors:  Susan L Tucker; Anwen Liu; Daniel Gomez; Ling Long Tang; Pamela Allen; Jinzhong Yang; Zhongxing Liao; David Grosshans
Journal:  Radiother Oncol       Date:  2016-05-14       Impact factor: 6.280

8.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

9.  Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

Authors:  Kyle Wang; Michael J Eblan; Allison M Deal; Matthew Lipner; Timothy M Zagar; Yue Wang; Panayiotis Mavroidis; Carrie B Lee; Brian C Jensen; Julian G Rosenman; Mark A Socinski; Thomas E Stinchcombe; Lawrence B Marks
Journal:  J Clin Oncol       Date:  2017-01-23       Impact factor: 50.717

Review 10.  American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology.

Authors:  Charles S Mayo; Jean M Moran; Walter Bosch; Ying Xiao; Todd McNutt; Richard Popple; Jeff Michalski; Mary Feng; Lawrence B Marks; Clifton D Fuller; Ellen Yorke; Jatinder Palta; Peter E Gabriel; Andrea Molineu; Martha M Matuszak; Elizabeth Covington; Kathryn Masi; Susan L Richardson; Timothy Ritter; Tomasz Morgas; Stella Flampouri; Lakshmi Santanam; Joseph A Moore; Thomas G Purdie; Robert C Miller; Coen Hurkmans; Judy Adams; Qing-Rong Jackie Wu; Colleen J Fox; Ramon Alfredo Siochi; Norman L Brown; Wilko Verbakel; Yves Archambault; Steven J Chmura; Andre L Dekker; Don G Eagle; Thomas J Fitzgerald; Theodore Hong; Rishabh Kapoor; Beth Lansing; Shruti Jolly; Mary E Napolitano; James Percy; Mark S Rose; Salim Siddiqui; Christof Schadt; William E Simon; William L Straube; Sara T St James; Kenneth Ulin; Sue S Yom; Torunn I Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-15       Impact factor: 7.038

View more
  12 in total

1.  Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer.

Authors:  Kyung Hwan Kim; Jaewon Oh; Gowoon Yang; Joongyo Lee; Jihun Kim; Seo-Yeon Gwak; Iksung Cho; Seung Hyun Lee; Hwa Kyung Byun; Hyo-Kyoung Choi; Jinsung Kim; Jee Suk Chang; Seok-Min Kang; Hong In Yoon
Journal:  JAMA Oncol       Date:  2022-09-22       Impact factor: 33.006

Review 2.  Radiation-Induced Cardiovascular Toxicities.

Authors:  Shahed N Badiyan; Lindsay L Puckett; Gregory Vlacich; Walter Schiffer; Lauren N Pedersen; Joshua D Mitchell; Carmen Bergom
Journal:  Curr Treat Options Oncol       Date:  2022-09-10

3.  Deep learning driven predictive treatment planning for adaptive radiotherapy of lung cancer.

Authors:  Donghoon Lee; Yu-Chi Hu; Licheng Kuo; Sadegh Alam; Ellen Yorke; Anyi Li; Andreas Rimner; Pengpeng Zhang
Journal:  Radiother Oncol       Date:  2022-02-18       Impact factor: 6.901

4.  Using Auto-Segmentation to Reduce Contouring and Dose Inconsistency in Clinical Trials: The Simulated Impact on RTOG 0617.

Authors:  Maria Thor; Aditya Apte; Rabia Haq; Aditi Iyer; Eve LoCastro; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-13       Impact factor: 7.038

5.  Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer.

Authors:  Louise Turtle; Neeraj Bhalla; Andrew Willett; Robert Biggar; Jonathan Leadbetter; Georgios Georgiou; James M Wilson; Sindu Vivekanandan; Maria A Hawkins; Michael Brada; John D Fenwick
Journal:  Radiat Oncol       Date:  2021-06-03       Impact factor: 3.481

Review 6.  Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.

Authors:  Jamie E Chaft; Andreas Rimner; Walter Weder; Christopher G Azzoli; Mark G Kris; Tina Cascone
Journal:  Nat Rev Clin Oncol       Date:  2021-04-28       Impact factor: 65.011

7.  Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort.

Authors:  Natalie Si-Yi Lee; Jesmin Shafiq; Matthew Field; Caroline Fiddler; Suganthy Varadarajan; Senthilkumar Gandhidasan; Eric Hau; Shalini Kavita Vinod
Journal:  Radiat Oncol       Date:  2022-04-13       Impact factor: 3.481

8.  Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab.

Authors:  Maria Thor; Annemarie F Shepherd; Isabel Preeshagul; Michael Offin; Daphna Y Gelblum; Abraham J Wu; Aditya Apte; Charles B Simone; Matthew D Hellmann; Andreas Rimner; Jamie E Chaft; Daniel R Gomez; Joseph O Deasy; Narek Shaverdian
Journal:  Radiother Oncol       Date:  2021-12-20       Impact factor: 6.901

9.  Cardio-pulmonary substructure segmentation of radiotherapy computed tomography images using convolutional neural networks for clinical outcomes analysis.

Authors:  Rabia Haq; Alexandra Hotca; Aditya Apte; Andreas Rimner; Joseph O Deasy; Maria Thor
Journal:  Phys Imaging Radiat Oncol       Date:  2020-06-10

10.  Quantifying inter-fraction cardiac substructure displacement during radiotherapy via magnetic resonance imaging guidance.

Authors:  Eric D Morris; Ahmed I Ghanem; Simeng Zhu; Ming Dong; Milan V Pantelic; Carri K Glide-Hurst
Journal:  Phys Imaging Radiat Oncol       Date:  2021-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.